[go: up one dir, main page]

IL129035A0 - 3-Mercaptoacetylamino-1,5-substituted-2-oxo- azepan derivatives useful as inhibitors of matrix metalloproteinase - Google Patents

3-Mercaptoacetylamino-1,5-substituted-2-oxo- azepan derivatives useful as inhibitors of matrix metalloproteinase

Info

Publication number
IL129035A0
IL129035A0 IL12903597A IL12903597A IL129035A0 IL 129035 A0 IL129035 A0 IL 129035A0 IL 12903597 A IL12903597 A IL 12903597A IL 12903597 A IL12903597 A IL 12903597A IL 129035 A0 IL129035 A0 IL 129035A0
Authority
IL
Israel
Prior art keywords
mercaptoacetylamino
oxo
inhibitors
substituted
matrix metalloproteinase
Prior art date
Application number
IL12903597A
Other languages
English (en)
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of IL129035A0 publication Critical patent/IL129035A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL12903597A 1996-09-19 1997-08-04 3-Mercaptoacetylamino-1,5-substituted-2-oxo- azepan derivatives useful as inhibitors of matrix metalloproteinase IL129035A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71929196A 1996-09-19 1996-09-19
PCT/US1997/013738 WO1998012211A1 (en) 1996-09-19 1997-08-04 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase

Publications (1)

Publication Number Publication Date
IL129035A0 true IL129035A0 (en) 2000-02-17

Family

ID=24889504

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12903597A IL129035A0 (en) 1996-09-19 1997-08-04 3-Mercaptoacetylamino-1,5-substituted-2-oxo- azepan derivatives useful as inhibitors of matrix metalloproteinase
IL129035A IL129035A (en) 1996-09-19 1999-03-17 History of 3 Mercaptoacetylamino 5, 1 - Transformed - 2 Oxo Azpan as Matroprotein Matrix Inhibitors, Pharmaceutical Preparations Containing Them and Their Use

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL129035A IL129035A (en) 1996-09-19 1999-03-17 History of 3 Mercaptoacetylamino 5, 1 - Transformed - 2 Oxo Azpan as Matroprotein Matrix Inhibitors, Pharmaceutical Preparations Containing Them and Their Use

Country Status (20)

Country Link
EP (1) EP0928291B1 (es)
JP (1) JP3962091B2 (es)
KR (1) KR100545460B1 (es)
CN (1) CN1150205C (es)
AR (1) AR009363A1 (es)
AT (1) ATE229034T1 (es)
AU (1) AU718055B2 (es)
BR (1) BR9713207A (es)
CA (1) CA2266759C (es)
DE (1) DE69717647T2 (es)
DK (1) DK0928291T3 (es)
ES (1) ES2184126T3 (es)
HU (1) HUP9904165A3 (es)
IL (2) IL129035A0 (es)
NO (1) NO991316L (es)
NZ (1) NZ334490A (es)
PT (1) PT928291E (es)
TW (1) TW445262B (es)
WO (1) WO1998012211A1 (es)
ZA (1) ZA978307B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040577A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6770640B1 (en) 1998-12-31 2004-08-03 Aventis Pharmaceuticals Inc. 1-Carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of MMP-12
AU1926500A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metallo-proteinases
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
AU760174B2 (en) 1999-02-09 2003-05-08 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
AU1588901A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
EP1229914A4 (en) 1999-11-10 2004-06-23 Smithkline Beecham Corp PROTEASE INHIBITORS
JP2003513972A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
KR20020082896A (ko) 2000-03-21 2002-10-31 스미스클라인 비참 코포레이션 프로테아제 억제제
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7704521B2 (en) 2007-04-11 2010-04-27 Zinpro Corporation Rumen protected essential amino acids
US20080255234A1 (en) * 2007-04-11 2008-10-16 Zinpro Corporation Rumen protected lysine
EP3630969B1 (en) 2017-05-31 2023-06-07 BRAIN Biotech AG Optimization of the expression of serine proteases in host cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2586942B2 (ja) * 1987-03-17 1997-03-05 リサーチ コーポレーシヨン テクノロジーズ インコーポレーテツド 哺乳動物コラゲナーゼの合成阻止剤
JPH07304746A (ja) * 1994-05-11 1995-11-21 Kanebo Ltd 新規ベンゾアゼピンカルボン酸誘導体
JP3787605B2 (ja) * 1994-10-05 2006-06-21 ダーウィン・ディスカバリー・リミテッド ペプチジル化合物および金属プロテアーゼのインヒビターとしてのその治療的使用
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids

Also Published As

Publication number Publication date
DE69717647T2 (de) 2003-09-25
ZA978307B (en) 1998-03-19
CN1150205C (zh) 2004-05-19
DK0928291T3 (da) 2003-03-17
WO1998012211A1 (en) 1998-03-26
AU3827897A (en) 1998-04-14
HUP9904165A2 (hu) 2000-03-28
NO991316L (no) 1999-05-18
CA2266759C (en) 2004-10-26
IL129035A (en) 2006-12-10
EP0928291A1 (en) 1999-07-14
AU718055B2 (en) 2000-04-06
ATE229034T1 (de) 2002-12-15
PT928291E (pt) 2003-03-31
JP2001501926A (ja) 2001-02-13
CN1234039A (zh) 1999-11-03
EP0928291B1 (en) 2002-12-04
JP3962091B2 (ja) 2007-08-22
BR9713207A (pt) 2000-04-04
NZ334490A (en) 2000-08-25
HK1020741A1 (en) 2000-05-19
NO991316D0 (no) 1999-03-18
HUP9904165A3 (en) 2002-01-28
TW445262B (en) 2001-07-11
DE69717647D1 (de) 2003-01-16
KR20000036246A (ko) 2000-06-26
CA2266759A1 (en) 1998-03-26
AR009363A1 (es) 2000-04-12
ES2184126T3 (es) 2003-04-01
KR100545460B1 (ko) 2006-01-24

Similar Documents

Publication Publication Date Title
IL130111A0 (en) 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors
PL331854A1 (en) Phosphinamides as inhibitors of metaloprotease matrix
AU8875798A (en) Meta-benzamidine derivatives as serin protease inhibitors
PL331254A1 (en) Phosphonianic inhibitors of matrix metaloproteases
IL128662A0 (en) Heterocyclic metalloprotease inhibitors
IL128664A0 (en) Heterocyclic metalloprotease inhibitors
AU4201799A (en) Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
AU8858398A (en) Matrix metalloproteinase inhibitors
IL129035A0 (en) 3-Mercaptoacetylamino-1,5-substituted-2-oxo- azepan derivatives useful as inhibitors of matrix metalloproteinase
PL329153A1 (en) Derivatives of pyrrolopyrolone as inhibitors of neutropil elastase
AU3342297A (en) Matrix metalloproteinase inhibitors
IL137162A0 (en) 2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors
HUP9904664A3 (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors
ZA975986B (en) N-alkoxyadenine derivatives acting as cytokine inhibitors.
AU1605699A (en) Substituted 3-amino-2-hydroxyphenylacetamide derivatives as enzyme inhibitors (ii)
HRP970247A2 (en) Substituted 4-arylbutric acid derivatives as matrix metalloprotease inhibitors
AU5128298A (en) Metalloproteinase inhibitors
HRP970246A2 (en) Substituted oxobutric acids as matrix metalloprotease inhibitors
AU9747098A (en) Aporphinoid matrix metalloproteinase inhibitors
AU7066398A (en) Novel use of matrix metalloproteinase inhibitors
SI0928291T1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
SI1001930T1 (en) N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
GB9702085D0 (en) Matrix metalloproteinase inhibitors
SI0901466T1 (en) Biphenylsulfonamide matrix metalloproteinase inhibitors
GB9627016D0 (en) Novel use of matrix metalloproteinase inhibitors

Legal Events

Date Code Title Description
KB Patent renewed
FF Patent granted
KB Patent renewed